Roche Inks Asset Purchase Agreement with Lumora
Swiss healthcare products giant Roche has signed a definitive agreement with Lumora to purchase assets associated with the latter’s patent-protected Heat Elution nucleic acid purification technology.
Roche will explore integrating the technology into its sequencing workflow solution. “Lumora’s Heat Elution technology can be integrated to an automated sequencing workflow, which makes it an ideal fit for Roche’s sequencing vision of a sample-in-results-out workflow,” says Dan Zabrowski, head of tissue diagnostics and sequencing at Roche.
According to Roche, nucleic acid purification technology from specimens is often inefficient, and Lumora's highly differentiated proprietary methodology will enable automated nucleic acid isolation within minutes, rather than hours.
Financial terms of the deal were not disclosed.
Lumora, based outside Cambridge, England, manufactures molecular diagnostic products for the clinical, nonclinical and industrial markets. — Michael Cipriano